Balaji Amines Ltd
Balaji Amines Ltd specialises in manufacturing Methylamines, Ethylamines, Derivatives of specialty chemicals and Pharma Excipients. These have been the main products, it also have facilities for the manufacturing of derivatives, which are down-stream products for various pharma/pesticide industries apart from user specific requirements. It is one of the largest manufacturers of aliphatic amines in India. [1]
- Market Cap ₹ 7,108 Cr.
- Current Price ₹ 2,194
- High / Low ₹ 2,736 / 1,960
- Stock P/E 40.1
- Book Value ₹ 474
- Dividend Yield 0.50 %
- ROCE 15.9 %
- ROE 11.6 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 7.06% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
509 | 608 | 602 | 632 | 665 | 858 | 947 | 918 | 1,227 | 1,914 | 1,720 | 1,332 | 1,333 | |
429 | 517 | 500 | 503 | 513 | 676 | 753 | 738 | 901 | 1,473 | 1,391 | 1,086 | 1,080 | |
Operating Profit | 80 | 91 | 102 | 129 | 151 | 182 | 193 | 180 | 327 | 441 | 330 | 247 | 254 |
OPM % | 16% | 15% | 17% | 20% | 23% | 21% | 20% | 20% | 27% | 23% | 19% | 19% | 19% |
4 | 3 | 3 | 2 | 9 | 12 | 5 | 10 | 12 | 18 | 10 | 21 | 22 | |
Interest | 25 | 32 | 31 | 20 | 12 | 9 | 13 | 12 | 5 | 7 | 3 | 2 | 2 |
Depreciation | 13 | 16 | 19 | 18 | 18 | 19 | 20 | 24 | 23 | 29 | 31 | 34 | 35 |
Profit before tax | 46 | 46 | 56 | 93 | 130 | 166 | 166 | 154 | 310 | 423 | 305 | 232 | 239 |
Tax % | 32% | 27% | 35% | 34% | 34% | 32% | 29% | 26% | 25% | 27% | 25% | 26% | |
31 | 34 | 36 | 61 | 86 | 113 | 118 | 114 | 232 | 308 | 228 | 171 | 177 | |
EPS in Rs | 9.62 | 10.35 | 11.22 | 18.91 | 26.41 | 34.93 | 36.44 | 35.11 | 71.51 | 95.04 | 70.23 | 52.87 | 54.74 |
Dividend Payout % | 14% | 10% | 11% | 11% | 8% | 7% | 8% | 9% | 6% | 6% | 14% | 21% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 7% |
3 Years: | 3% |
TTM: | -14% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 8% |
3 Years: | -10% |
TTM: | 5% |
Stock Price CAGR | |
---|---|
10 Years: | 38% |
5 Years: | 54% |
3 Years: | -17% |
1 Year: | -4% |
Return on Equity | |
---|---|
10 Years: | 21% |
5 Years: | 20% |
3 Years: | 19% |
Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Reserves | 166 | 196 | 231 | 285 | 371 | 461 | 569 | 661 | 891 | 1,186 | 1,394 | 1,528 |
209 | 262 | 236 | 159 | 103 | 115 | 95 | 102 | 0 | 0 | 0 | 0 | |
139 | 158 | 129 | 156 | 175 | 237 | 327 | 334 | 394 | 292 | 151 | 202 | |
Total Liabilities | 520 | 621 | 603 | 607 | 655 | 819 | 997 | 1,104 | 1,292 | 1,484 | 1,551 | 1,736 |
234 | 325 | 321 | 322 | 309 | 316 | 318 | 363 | 344 | 495 | 604 | 724 | |
CWIP | 63 | 8 | 3 | 16 | 25 | 66 | 63 | 46 | 173 | 141 | 74 | 143 |
Investments | 21 | 21 | 30 | 30 | 30 | 66 | 66 | 114 | 66 | 66 | 128 | 66 |
203 | 268 | 249 | 238 | 292 | 371 | 550 | 581 | 708 | 782 | 745 | 803 | |
Total Assets | 520 | 621 | 603 | 607 | 655 | 819 | 997 | 1,104 | 1,292 | 1,484 | 1,551 | 1,736 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
94 | 111 | 60 | 84 | 72 | 126 | 89 | 148 | 94 | 176 | 187 | 170 | |
-86 | -50 | -14 | -30 | -23 | -93 | -47 | -130 | -87 | -142 | -155 | -144 | |
-10 | -53 | -49 | -52 | -54 | -29 | -29 | -31 | 3 | -20 | -22 | -35 | |
Net Cash Flow | -2 | 7 | -3 | 2 | -5 | 4 | 13 | -13 | 10 | 14 | 10 | -8 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 74 | 79 | 70 | 69 | 67 | 73 | 64 | 76 | 81 | 83 | 55 | 72 |
Inventory Days | 66 | 87 | 93 | 62 | 88 | 70 | 100 | 66 | 56 | 69 | 97 | 127 |
Days Payable | 42 | 83 | 46 | 57 | 55 | 56 | 58 | 40 | 43 | 57 | 13 | 35 |
Cash Conversion Cycle | 99 | 83 | 117 | 74 | 100 | 87 | 106 | 102 | 94 | 95 | 139 | 163 |
Working Capital Days | 75 | 67 | 85 | 58 | 67 | 71 | 82 | 87 | 80 | 80 | 98 | 118 |
ROCE % | 19% | 18% | 19% | 24% | 30% | 33% | 29% | 23% | 38% | 41% | 24% | 16% |
Documents
Announcements
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
14 Aug - Regarding Grant of Environmental Clearance (EC) to the proposed Greenfield Project of Balaji Speciality Chemicals Limited, Material Subsidiary Company
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Aug - Copy of Newspaper Advertisements of Extract of Standalone and Consolidated Financial Results of the Company for the Quarter ended 30th June, 2024, published in Business …
- Announcement under Regulation 30 (LODR)-Investor Presentation 8 Aug
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
7 Aug - Press Release in connection with the Un-audited Financial Results of the Company for the Quarter ended 30th June, 2024
- Board Meeting Outcome for Outcome Of Board Meeting 7 Aug
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptPPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Oct 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jul 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Jan 2020TranscriptNotesPPT
-
Dec 2019Transcript PPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019Transcript PPT
-
Jul 2019TranscriptNotesPPT
-
May 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Feb 2017TranscriptPPT
-
Feb 2017TranscriptPPT
Product Portfolio[1]
The company has a diversified product portfolio with a basket of ~30 different products. These products are categorized under 3 main categories i.e. Amines, Amine derivatives, and Specialty & Other chemicals. Its products include Methyl Amines, Ethyl amines, Amino Ethanol, acetamide, amine hydrochloride, methyl urea, choline chloride, morpholine, etc.
Its products find application in many industries like Pharma, Agro, Rubber chemicals, photographic chemicals, rocket fuel, pesticides, solvents, performance chemicals, water treatment chemicals, etc.